Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Male Urogenital Diseases D052801 1 associated lipids
Trichiasis D058457 1 associated lipids
Reproductive Tract Infections D060737 1 associated lipids
Corneal Endothelial Cell Loss D055954 1 associated lipids
Frontal Sinusitis D015522 1 associated lipids
Hyper-IgM Immunodeficiency Syndrome D053306 1 associated lipids
Paratyphoid Fever D010284 1 associated lipids
Asymptomatic Infections D058345 1 associated lipids
T-Lymphocytopenia, Idiopathic CD4-Positive D018344 1 associated lipids
Ectodermal Dysplasia D004476 1 associated lipids
Aphasia, Broca D001039 1 associated lipids
Acquired Hyperostosis Syndrome D020083 1 associated lipids
Myelitis, Transverse D009188 1 associated lipids
Epiglottitis D004826 1 associated lipids
Tick Bites D064927 1 associated lipids
Eisenmenger Complex D004541 1 associated lipids
Furcation Defects D017823 1 associated lipids
Granulomatous Mastitis D058890 1 associated lipids
Focal Nodular Hyperplasia D020518 1 associated lipids
Syncope, Vasovagal D019462 1 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Saint-Criq V et al. Restoration of chloride efflux by azithromycin in airway epithelial cells of cystic fibrosis patients. 2011 Antimicrob. Agents Chemother. pmid:21220528
Sato T et al. In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila. 2011 Antimicrob. Agents Chemother. pmid:21220530
Lu Y et al. Antibiotics Promote Escherichia coli-Pseudomonas aeruginosa Conjugation through Inhibiting Quorum Sensing. 2017 Antimicrob. Agents Chemother. pmid:28993333
Waag DM Efficacy of postexposure therapy against glanders in mice. 2015 Antimicrob. Agents Chemother. pmid:25645854
Peric M et al. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. 2003 Antimicrob. Agents Chemother. pmid:12604536
Seral C et al. Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages. 2003 Antimicrob. Agents Chemother. pmid:12604540
Imamura Y et al. Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 Cells. 2004 Antimicrob. Agents Chemother. pmid:15328111
Odenholt-Tornqvist I et al. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. 1995 Antimicrob. Agents Chemother. pmid:7695310
Roblin PM et al. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. 2003 Antimicrob. Agents Chemother. pmid:12604555
Malinverni R et al. Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis. 1995 Antimicrob. Agents Chemother. pmid:7695327
Rodvold KA et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. 1997 Antimicrob. Agents Chemother. pmid:9174209
Solomon AW et al. Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. 2005 Antimicrob. Agents Chemother. pmid:16251338
Kirkcaldy RD et al. Analysis of Neisseria gonorrhoeae azithromycin susceptibility in the United States by the Gonococcal Isolate Surveillance Project, 2005 to 2013. 2015 Antimicrob. Agents Chemother. pmid:25451056
Koeva M et al. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections. 2017 Antimicrob. Agents Chemother. pmid:28923873
Nahata MC et al. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. 1993 Antimicrob. Agents Chemother. pmid:8383944
Vaara M Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. 1993 Antimicrob. Agents Chemother. pmid:8383945
Brown ST et al. Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine. 1993 Antimicrob. Agents Chemother. pmid:8384809
Goldman RC et al. Role of protonated and neutral forms of macrolides in binding to ribosomes from gram-positive and gram-negative bacteria. 1990 Antimicrob. Agents Chemother. pmid:2159256
Ohrt C et al. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. 2002 Antimicrob. Agents Chemother. pmid:12121927
Gladue RP and Snider ME Intracellular accumulation of azithromycin by cultured human fibroblasts. 1990 Antimicrob. Agents Chemother. pmid:2168141
Feola DJ et al. Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. 2010 Antimicrob. Agents Chemother. pmid:20231397
Riska PF et al. Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae. 2004 Antimicrob. Agents Chemother. pmid:15328134
Goldstein EJ et al. Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. 1999 Antimicrob. Agents Chemother. pmid:10543769
Watt G et al. Azithromycin activities against Orientia tsutsugamushi strains isolated in cases of scrub typhus in Northern Thailand. 1999 Antimicrob. Agents Chemother. pmid:10543774
Kutlin A et al. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. 1999 Antimicrob. Agents Chemother. pmid:10471577
Hultén K et al. New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. 1996 Antimicrob. Agents Chemother. pmid:9124830
Bui KQ et al. Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis. 1999 Antimicrob. Agents Chemother. pmid:10471584
Jacobsson S et al. Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant Neisseria gonorrhoeae. 2017 Antimicrob. Agents Chemother. pmid:28893785
Zarantonelli L et al. Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. 1999 Antimicrob. Agents Chemother. pmid:10508026
Sugie M et al. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. 2004 Antimicrob. Agents Chemother. pmid:14982769
Loreto ES et al. New insights into the in vitro susceptibility of Pythium insidiosum. 2014 Antimicrob. Agents Chemother. pmid:25223997
Schmalstieg AM et al. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. 2012 Antimicrob. Agents Chemother. pmid:22751536
Caceres SM et al. Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products. 2014 Antimicrob. Agents Chemother. pmid:25182651
den Hollander JG et al. Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. 1998 Antimicrob. Agents Chemother. pmid:9527789
Bulman ZP et al. Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin. 2017 Antimicrob. Agents Chemother. pmid:28096154
Pandori MW et al. Detection of azithromycin resistance in Treponema pallidum by real-time PCR. 2007 Antimicrob. Agents Chemother. pmid:17620374
Hoffmann N et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. 2007 Antimicrob. Agents Chemother. pmid:17620382
Capobianco JO and Goldman RC Erythromycin and azithromycin transport into Haemophilus influenzae ATCC 19418 under conditions of depressed proton motive force (delta mu H). 1990 Antimicrob. Agents Chemother. pmid:2178338
Descours G et al. Ribosomal Mutations Conferring Macrolide Resistance in Legionella pneumophila. 2017 Antimicrob. Agents Chemother. pmid:28069647
Gorby GL and McGee ZA Antimicrobial interference with bacterial mechanisms of pathogenicity: effect of sub-MIC azithromycin on gonococcal piliation and attachment to human epithelial cells. 1990 Antimicrob. Agents Chemother. pmid:1982402
Bonnet M and Van der Auwera P Preincubation of Haemophilus influenzae with subinhibitory concentrations of macrolides: influence on human neutrophil chemiluminescence. 1993 Antimicrob. Agents Chemother. pmid:8390808
Gordillo ME et al. In vitro activity of azithromycin against bacterial enteric pathogens. 1993 Antimicrob. Agents Chemother. pmid:8390813
Kohlhoff SA et al. In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae. 2004 Antimicrob. Agents Chemother. pmid:15105151
Brieland JK et al. Efficacy of SCH27899 in an animal model of Legionnaires' disease using immunocompromised A/J mice. 2000 Antimicrob. Agents Chemother. pmid:10770771
Luke DR et al. Safety, toleration, and pharmacokinetics of intravenous azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8913468
Olsen KM et al. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. 1996 Antimicrob. Agents Chemother. pmid:8913469
Hogan PA and Sheehan DJ Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997. 1998 Antimicrob. Agents Chemother. pmid:9835536
Geisler WM et al. Randomized, double-blind, multicenter safety and efficacy study of rifalazil compared with azithromycin for treatment of uncomplicated genital Chlamydia trachomatis infection in women. 2014 Antimicrob. Agents Chemother. pmid:24798277
Kobuchi S et al. Transport of Azithromycin into Extravascular Space in Rats. 2016 Antimicrob. Agents Chemother. pmid:27600045
Mukherjee P et al. Emergence of high-level azithromycin resistance in Campylobacter jejuni isolates from pediatric diarrhea patients in Kolkata, India. 2014 Antimicrob. Agents Chemother. pmid:24777098
Goldman RC and Capobianco JO Role of an energy-dependent efflux pump in plasmid pNE24-mediated resistance to 14- and 15-membered macrolides in Staphylococcus epidermidis. 1990 Antimicrob. Agents Chemother. pmid:1963291
Achard A et al. Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene. 2008 Antimicrob. Agents Chemother. pmid:18519724
Rouse MS et al. Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. 1997 Antimicrob. Agents Chemother. pmid:9257739
Hoppe JE and Bryskier A In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). 1998 Antimicrob. Agents Chemother. pmid:9559823
Yoshioka D et al. Efficacy of β-Lactam-plus-Macrolide Combination Therapy in a Mouse Model of Lethal Pneumococcal Pneumonia. 2016 Antimicrob. Agents Chemother. pmid:27480866
Jeong BH et al. Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease. 2016 Antimicrob. Agents Chemother. pmid:27480854
Mallegol J et al. Antimicrobial activity of solithromycin against clinical isolates of Legionella pneumophila serogroup 1. 2014 Antimicrob. Agents Chemother. pmid:24277019
Bermudez LE et al. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. 2001 Antimicrob. Agents Chemother. pmid:11120969
Oh YK et al. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. 1995 Antimicrob. Agents Chemother. pmid:8540724
Fuentes F et al. Postanitbiotic and sub-MIC effects of azithromycin and isepamicin against Staphylococcus aureus and Escherichia coli. 1998 Antimicrob. Agents Chemother. pmid:9527796
Kashuba AD and Amsden GW Bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. 1998 Antimicrob. Agents Chemother. pmid:9527816
Noedl H et al. In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. 2007 Antimicrob. Agents Chemother. pmid:17116669
Itaqui SR et al. In Vitro Synergism between Azithromycin or Terbinafine and Topical Antimicrobial Agents against Pythium insidiosum. 2016 Antimicrob. Agents Chemother. pmid:27216049
Matic V et al. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. 2004 Antimicrob. Agents Chemother. pmid:15504828
Visalli MA et al. Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin. 1997 Antimicrob. Agents Chemother. pmid:9303375
Ednie LM et al. Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). 1997 Antimicrob. Agents Chemother. pmid:9303406
Roblin PM et al. In vitro activity of trovafloxacin against Chlamydia pneumoniae. 1997 Antimicrob. Agents Chemother. pmid:9303410
Nahata MC et al. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. 1995 Antimicrob. Agents Chemother. pmid:7486938
Tomazic J et al. Ex vivo effect of azithromycin in human leukocyte bactericidal functions. 1995 Antimicrob. Agents Chemother. pmid:7486947
Ouyang-Latimer J et al. In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008. 2011 Antimicrob. Agents Chemother. pmid:21115800
Frank MO et al. In vitro demonstration of transport and delivery of antibiotics by polymorphonuclear leukocytes. 1992 Antimicrob. Agents Chemother. pmid:1336337
O'Reilly T et al. Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin. 1992 Antimicrob. Agents Chemother. pmid:1336342
Wolinsky E Mycobacterium avium strains resistant to clarithromycin and azithromycin. 1994 Antimicrob. Agents Chemother. pmid:8031406
Taylor WR et al. Tolerability of azithromycin as malaria prophylaxis in adults in northeast papua, indonesia. 2003 Antimicrob. Agents Chemother. pmid:12821468
Nakajima T et al. Microbiological and Clinical Effects of Sitafloxacin and Azithromycin in Periodontitis Patients Receiving Supportive Periodontal Therapy. 2016 Antimicrob. Agents Chemother. pmid:26729495
Seral C et al. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. 2003 Antimicrob. Agents Chemother. pmid:12821480
Ravdin JI and Skilogiannis J In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole. 1989 Antimicrob. Agents Chemother. pmid:2548442
Bermudez LE and Young LS Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex. 1988 Antimicrob. Agents Chemother. pmid:2847644
Salman S et al. Pharmacokinetics of Transfer of Azithromycin into the Breast Milk of African Mothers. 2015 Antimicrob. Agents Chemother. pmid:26711756
Kawai Y et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. 2013 Antimicrob. Agents Chemother. pmid:23459497
Viscardi RM et al. Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose. 2013 Antimicrob. Agents Chemother. pmid:23439637
Cynamon MH et al. Comparative activities of azithromycin and clarithromycin against Mycobacterium avium infection in beige mice. 1994 Antimicrob. Agents Chemother. pmid:7979270
Ressner RA et al. Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. 2008 Antimicrob. Agents Chemother. pmid:18411316
Carvalho-Assef AP et al. Detection of NDM-1-, CTX-M-15-, and qnrB4-producing Enterobacter hormaechei isolates in Brazil. 2014 Antimicrob. Agents Chemother. pmid:24449772
Goldstein EJ et al. Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. 1998 Antimicrob. Agents Chemother. pmid:9593139
Spangler SK et al. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. 1998 Antimicrob. Agents Chemother. pmid:9593160
Pankuch GA et al. In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae. 1998 Antimicrob. Agents Chemother. pmid:9797225
Roblin PM and Hammerschlag MR In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. 1998 Antimicrob. Agents Chemother. pmid:9624507
Bergman M et al. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. 2006 Antimicrob. Agents Chemother. pmid:16940064
Gladue RP et al. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. 1989 Antimicrob. Agents Chemother. pmid:2543276
Woosley LN et al. CEM-101 activity against Gram-positive organisms. 2010 Antimicrob. Agents Chemother. pmid:20176910
Araujo FG et al. Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii. 1988 Antimicrob. Agents Chemother. pmid:2840017
Pereira MR et al. In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipine. 2011 Antimicrob. Agents Chemother. pmid:21464242
Odenholt I et al. Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase. 1997 Antimicrob. Agents Chemother. pmid:9371360
Kosowska-Shick K et al. Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis. 2006 Antimicrob. Agents Chemother. pmid:17043120
Garey KW et al. Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. 1999 Antimicrob. Agents Chemother. pmid:10223928
Ouadrhiri Y et al. Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by gamma interferon. 1999 Antimicrob. Agents Chemother. pmid:10223943
Phillips-Campbell R et al. Induction of the Chlamydia muridarum stress/persistence response increases azithromycin treatment failure in a murine model of infection. 2014 Antimicrob. Agents Chemother. pmid:24342653
Könönen E et al. beta-lactamase production and antimicrobial susceptibility of oral heterogeneous Fusobacterium nucleatum populations in young children. 1999 Antimicrob. Agents Chemother. pmid:10223950
Jang MO et al. Outcome of intravenous azithromycin therapy in patients with complicated scrub typhus compared with that of doxycycline therapy using propensity-matched analysis. 2014 Antimicrob. Agents Chemother. pmid:24366734